vs
Side-by-side financial comparison of JFrog Ltd (FROG) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
Nutex Health, Inc. is the larger business by last-quarter revenue ($151.7M vs $145.3M, roughly 1.0× JFrog Ltd). Nutex Health, Inc. runs the higher net margin — 7.8% vs -10.5%, a 18.3% gap on every dollar of revenue. On growth, JFrog Ltd posted the faster year-over-year revenue change (25.2% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $49.9M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 20.4%).
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
FROG vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $145.3M | $151.7M |
| Net Profit | $-15.2M | $11.8M |
| Gross Margin | 77.9% | 30.4% |
| Operating Margin | -14.7% | 20.4% |
| Net Margin | -10.5% | 7.8% |
| Revenue YoY | 25.2% | -41.1% |
| Net Profit YoY | 34.4% | -80.8% |
| EPS (diluted) | $-0.13 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $145.3M | $151.7M | ||
| Q3 25 | $136.9M | $267.8M | ||
| Q2 25 | $127.2M | $244.0M | ||
| Q1 25 | $122.4M | $211.8M | ||
| Q4 24 | $116.1M | $257.6M | ||
| Q3 24 | $109.1M | $78.8M | ||
| Q2 24 | $103.0M | $76.1M | ||
| Q1 24 | $100.3M | $67.5M |
| Q4 25 | $-15.2M | $11.8M | ||
| Q3 25 | $-16.4M | $55.4M | ||
| Q2 25 | $-21.7M | $-17.7M | ||
| Q1 25 | $-18.5M | $21.2M | ||
| Q4 24 | $-23.2M | $61.6M | ||
| Q3 24 | $-22.9M | $-8.8M | ||
| Q2 24 | $-14.3M | $-364.0K | ||
| Q1 24 | $-8.8M | $-364.0K |
| Q4 25 | 77.9% | 30.4% | ||
| Q3 25 | 77.4% | 57.8% | ||
| Q2 25 | 76.3% | 51.2% | ||
| Q1 25 | 75.3% | 55.9% | ||
| Q4 24 | 75.4% | 55.0% | ||
| Q3 24 | 75.0% | 27.8% | ||
| Q2 24 | 78.8% | 29.7% | ||
| Q1 24 | 79.5% | 15.1% |
| Q4 25 | -14.7% | 20.4% | ||
| Q3 25 | -15.8% | 48.7% | ||
| Q2 25 | -20.4% | 13.8% | ||
| Q1 25 | -18.8% | 38.1% | ||
| Q4 24 | -21.9% | 44.4% | ||
| Q3 24 | -27.4% | 12.3% | ||
| Q2 24 | -18.6% | 7.0% | ||
| Q1 24 | -16.6% | 2.1% |
| Q4 25 | -10.5% | 7.8% | ||
| Q3 25 | -12.0% | 20.7% | ||
| Q2 25 | -17.0% | -7.3% | ||
| Q1 25 | -15.1% | 10.0% | ||
| Q4 24 | -20.0% | 23.9% | ||
| Q3 24 | -21.0% | -11.2% | ||
| Q2 24 | -13.9% | -0.5% | ||
| Q1 24 | -8.8% | -0.5% |
| Q4 25 | $-0.13 | $2.34 | ||
| Q3 25 | $-0.14 | $7.76 | ||
| Q2 25 | $-0.19 | $-2.95 | ||
| Q1 25 | $-0.16 | $3.33 | ||
| Q4 24 | $-0.21 | $11.56 | ||
| Q3 24 | $-0.21 | $-1.72 | ||
| Q2 24 | $-0.13 | $-0.07 | ||
| Q1 24 | $-0.08 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $704.4M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $887.4M | $329.4M |
| Total Assets | $1.3B | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $704.4M | $185.6M | ||
| Q3 25 | $651.1M | $166.0M | ||
| Q2 25 | $611.7M | $96.7M | ||
| Q1 25 | $563.5M | $84.7M | ||
| Q4 24 | $522.0M | $40.6M | ||
| Q3 24 | $467.8M | $46.9M | ||
| Q2 24 | $591.3M | $40.8M | ||
| Q1 24 | $579.6M | $30.0M |
| Q4 25 | $887.4M | $329.4M | ||
| Q3 25 | $859.4M | $317.2M | ||
| Q2 25 | $826.5M | $235.3M | ||
| Q1 25 | $800.0M | $176.9M | ||
| Q4 24 | $773.5M | $132.4M | ||
| Q3 24 | $756.2M | $60.4M | ||
| Q2 24 | $721.4M | $62.7M | ||
| Q1 24 | $707.8M | $63.0M |
| Q4 25 | $1.3B | $918.5M | ||
| Q3 25 | $1.3B | $964.5M | ||
| Q2 25 | $1.2B | $841.0M | ||
| Q1 25 | $1.2B | $761.9M | ||
| Q4 24 | $1.1B | $655.3M | ||
| Q3 24 | $1.1B | $438.5M | ||
| Q2 24 | $1.0B | $422.4M | ||
| Q1 24 | $997.1M | $404.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $50.7M | $70.4M |
| Free Cash FlowOCF − Capex | $49.9M | $69.0M |
| FCF MarginFCF / Revenue | 34.3% | 45.5% |
| Capex IntensityCapex / Revenue | 0.6% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $142.3M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.7M | $70.4M | ||
| Q3 25 | $30.2M | $99.5M | ||
| Q2 25 | $36.1M | $27.3M | ||
| Q1 25 | $28.8M | $51.0M | ||
| Q4 24 | $49.1M | $54.0K | ||
| Q3 24 | $27.6M | $6.8M | ||
| Q2 24 | $16.7M | $13.3M | ||
| Q1 24 | $17.5M | $3.1M |
| Q4 25 | $49.9M | $69.0M | ||
| Q3 25 | $28.8M | $99.2M | ||
| Q2 25 | $35.5M | $26.5M | ||
| Q1 25 | $28.1M | $50.9M | ||
| Q4 24 | $48.5M | $-341.0K | ||
| Q3 24 | $26.7M | $6.2M | ||
| Q2 24 | $16.0M | $12.7M | ||
| Q1 24 | $16.6M | $2.3M |
| Q4 25 | 34.3% | 45.5% | ||
| Q3 25 | 21.0% | 37.0% | ||
| Q2 25 | 27.9% | 10.9% | ||
| Q1 25 | 23.0% | 24.0% | ||
| Q4 24 | 41.8% | -0.1% | ||
| Q3 24 | 24.5% | 7.8% | ||
| Q2 24 | 15.5% | 16.7% | ||
| Q1 24 | 16.6% | 3.4% |
| Q4 25 | 0.6% | 0.9% | ||
| Q3 25 | 1.0% | 0.1% | ||
| Q2 25 | 0.5% | 0.3% | ||
| Q1 25 | 0.5% | 0.0% | ||
| Q4 24 | 0.5% | 0.2% | ||
| Q3 24 | 0.9% | 0.8% | ||
| Q2 24 | 0.7% | 0.7% | ||
| Q1 24 | 0.8% | 1.1% |
| Q4 25 | — | 5.95× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FROG
Segment breakdown not available.
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
